Cutler Group LP Alzamend Neuro, Inc. Transaction History

Cutler Group LP

  • $307 Million
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 14, 2022
SELL
$0.91 - $2.23 $11,263 - $27,602
-12,378 Closed
0 $0
Q4 2021

Jan 18, 2022
BUY
$1.9 - $3.08 $14,018 - $22,724
7,378 Added 147.56%
12,378 $23,000
Q3 2021

Oct 26, 2021
BUY
$2.28 - $7.68 $11,399 - $38,400
5,000 New
5,000 $15,000

About Alzamend Neuro, Inc.

ALZN Quotes by TradingView
  • Ticker ALZN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 95,481,800
  • Market Cap $115M
  • Description
  • Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...
More about ALZN
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email